Have a feature idea you'd love to see implemented?
Let us know!
ABCL AbCellera Biologics Inc
Price (delayed)
$2.72
Market cap
$803.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.61
Enterprise value
$718.03M
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners
Highlights
AbCellera Biologics's debt has decreased by 12% YoY
The company's quick ratio fell by 15% QoQ but it rose by 14% YoY
ABCL's EPS is down by 36% YoY and by 13% from the previous quarter
AbCellera Biologics's net income has decreased by 36% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of ABCL
Market
Valuations
Earnings
Shares outstanding
295.37M
Market cap
$803.4M
Enterprise value
$718.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
24.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.78
Revenue
$32.96M
EBIT
-$202.17M
EBITDA
-$109.96M
Free cash flow
-$197.36M
Per share
Balance sheet
Liquidity
EPS
-$0.61
Free cash flow per share
-$0.67
Book value per share
$3.66
Revenue per share
$0.11
TBVPS
$4.38
Total assets
$1.39B
Total liabilities
$314.73M
Debt
$66.27M
Equity
$1.08B
Working capital
$663.32M
Debt to equity
0.06
Current ratio
9.34
Quick ratio
8.79
Net debt/EBITDA
0.78
Margins
Efficiency
Dividend
EBITDA margin
-333.6%
Gross margin
100%
Net margin
-533.3%
Operating margin
-934.6%
Return on assets
-12.2%
Return on equity
-15.7%
Return on invested capital
-18.2%
Return on capital employed
-15.4%
Return on sales
-613.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABCL stock price
How has the AbCellera Biologics stock price performed over time
Intraday
1.87%
1 week
-1.45%
1 month
-1.81%
1 year
-37.33%
YTD
-52.36%
QTD
4.62%
Financial performance
How have AbCellera Biologics's revenue and profit performed over time
Revenue
$32.96M
Gross profit
$32.96M
Operating income
-$308.06M
Net income
-$175.8M
Gross margin
100%
Net margin
-533.3%
AbCellera Biologics's operating margin has shrunk by 125% YoY and by 15% QoQ
AbCellera Biologics's net margin has plunged by 108% YoY and by 15% from the previous quarter
ABCL's operating income is down by 47% year-on-year and by 14% since the previous quarter
AbCellera Biologics's net income has decreased by 36% YoY and by 15% from the previous quarter
Growth
What is AbCellera Biologics's growth rate over time
Valuation
What is AbCellera Biologics stock price valuation
P/E
N/A
P/B
0.74
P/S
24.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.78
ABCL's EPS is down by 36% YoY and by 13% from the previous quarter
ABCL's P/B is 79% below its 5-year quarterly average of 3.5 and 27% below its last 4 quarters average of 1.0
The equity has declined by 9% year-on-year and by 3% since the previous quarter
The company's revenue fell by 35% YoY
The P/S is 32% more than the 5-year quarterly average of 18.1 but 27% less than the last 4 quarters average of 32.5
Efficiency
How efficient is AbCellera Biologics business performance
ABCL's ROS has plunged by 97% YoY and by 13% from the previous quarter
AbCellera Biologics's ROE has decreased by 47% YoY and by 17% from the previous quarter
The ROA has contracted by 44% YoY and by 17% from the previous quarter
The company's return on invested capital fell by 22% YoY and by 13% QoQ
Dividends
What is ABCL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABCL.
Financial health
How did AbCellera Biologics financials performed over time
The company's quick ratio fell by 15% QoQ but it rose by 14% YoY
ABCL's current ratio is down by 15% QoQ but it is up by 12% YoY
AbCellera Biologics's debt is 94% less than its equity
AbCellera Biologics's debt has decreased by 12% YoY
The equity has declined by 9% year-on-year and by 3% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.